CRDF
NASDAQCardiff Oncology Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$1.22-0.69 (-36.39%)
2026-03-172026-06-18
News · 26 weeks49+83%
2025-12-282026-06-21
Mix3490d
- Insider12(35%)
- SEC Filings9(26%)
- Other8(24%)
- Analyst3(9%)
- Leadership1(3%)
- Earnings1(3%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Tannenbaum Renee P4 - Cardiff Oncology, Inc. (0001213037) (Issuer)
- INSIDERSEC Form 4 filed by Director Pace Gary W4 - Cardiff Oncology, Inc. (0001213037) (Issuer)
- INSIDERSEC Form 4 filed by Director Markin Rodney S4 - Cardiff Oncology, Inc. (0001213037) (Issuer)
- INSIDERSEC Form 4 filed by Director White Lale4 - Cardiff Oncology, Inc. (0001213037) (Issuer)
- INSIDERSEC Form 4 filed by Director Armitage James O4 - Cardiff Oncology, Inc. (0001213037) (Issuer)
- ANALYSTCardiff Oncology downgraded by Craig Hallum with a new price targetCraig Hallum downgraded Cardiff Oncology from Buy to Hold and set a new price target of $2.00
- SECCardiff Oncology Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Cardiff Oncology, Inc. (0001213037) (Filer)
- PRCardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting- The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regimen for the registrational program - - 30 mg onvansertib + FOLFIRI/bevacizumab arm showed a dose-dependent improvement in efficacy, including confirmed ORR of 72.2% compared to 42.1% for SoC - - Median PFS has not been reached in either 20 or 30 mg onvansertib + FOLFIRI/bevacizumab arm, with nine of the 14 patients remaining on treatment in these arms - - Onvansertib continues to be safe and well-tolerated with no overlapping or new toxicities when added to SoC - - Registrational trial planned in first-line RAS-mutated mCRC following successful End-of-Phase
- PRCardiff Oncology to Participate in the Jefferies Global Healthcare ConferenceSAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the Jefferies Global Healthcare Conference on June 2-4, 2026. Details of the presentation can be found below. Format: Fireside ChatPresenter: Mani Mohindru, PhD (President and CEO) Date: 06/04/2026 Time: 10:30 -11:00 AM ET Interested parties can register for and access the live webcast for the conference by visiting the "Events" section of the Cardiff Oncology website. The webcast repl
- ANALYSTCardiff Oncology downgraded by H.C. WainwrightH.C. Wainwright downgraded Cardiff Oncology from Buy to Neutral
- ANALYSTCardiff Oncology downgraded by TD CowenTD Cowen downgraded Cardiff Oncology from Buy to Hold
- SECCardiff Oncology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - Cardiff Oncology, Inc. (0001213037) (Filer)
- PRCardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRCSAN DIEGO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced that it will host an investor webcast featuring members of management on June 3, 2026 at 8:30 am ET to review updated data from CRDF-004, a randomized dose-finding Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care regimens (FOLFIRI/bevacizumab or FOLFOX/bevacizumab) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). The updated CRDF-004 data will first be presented during a rapid oral session at the 2026 American Society of Cli
- SECCardiff Oncology Inc. filed SEC Form 8-K: Other Events8-K - Cardiff Oncology, Inc. (0001213037) (Filer)
- SECCardiff Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Cardiff Oncology, Inc. (0001213037) (Filer)
- PRCardiff Oncology Reports First Quarter 2026 Results and Provides Business UpdateCompleted successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial Company to provide detailed data update from Phase 2 CRDF-004 trial in rapid oral presentation at American Society of Clinical Oncology Annual Meeting Leadership additions position Company to execute on key upcoming clinical and regulatory milestones SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced financial results for the first quarter ended March 31, 2026, and provided a business update. "This qua
- SECSEC Form 10-Q filed by Cardiff Oncology Inc.10-Q - Cardiff Oncology, Inc. (0001213037) (Filer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Aggarwal Ajay4 - Cardiff Oncology, Inc. (0001213037) (Issuer)
- INSIDERSEC Form 3 filed by new insider Aggarwal Ajay3 - Cardiff Oncology, Inc. (0001213037) (Issuer)
- PRCardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, announced that in connection with Dr. Aggarwal joining Cardiff Oncology as Chief Operating Officer, the Company's Compensation Committee approved the grant of non-qualified stock options to purchase 400,000 shares of Cardiff Oncology common stock outside of the Cardiff Oncology 2021 Omnibus Equity Incentive Plan. The stock option was granted as an inducement material to Dr. Aggarwal becoming an employee of Cardiff Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The opti
- PRCardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib's Promising Single-Agent ActivitySAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that the Company will host a key opinion leader (KOL) webinar to discuss data from an investigator-initiated trial on onvansertib's single-agent clinical activity in chronic myelomonocytic leukemia (CMML). The webinar will take place on Thursday, April 30th, 2026, at 11:00 a.m. ET. The webinar will feature KOL Mrinal Patnaik, MBBS, a physician scientist with the Division of Hematology, Department of Internal Medicine at Mayo Clinic, Minnesota. He is the Chair of the Acute
- SECSEC Form DEFA14A filed by Cardiff Oncology Inc.DEFA14A - Cardiff Oncology, Inc. (0001213037) (Filer)
- SECSEC Form DEF 14A filed by Cardiff Oncology Inc.DEF 14A - Cardiff Oncology, Inc. (0001213037) (Filer)
- PRCardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced it will present updated data from CRDF-004, a randomized dose-finding Phase 2 clinical trial evaluating onvansertib in combination with standard of care (SoC) regimens (FOLFIRI/bevacizumab (bev) or FOLFOX/bev) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). The data will be reviewed in a rapid oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29–June 2 in Chicago. Rapid Oral Presentation Details: Abstrac
- PRCardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual MeetingSAN DIEGO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, will present new preclinical data in a poster at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17–22 in San Diego, California. These data highlight the potential of Cardiff's highly specific oral PLK1 inhibitor, onvansertib, in combination with the HER2-targeted antibody-drug conjugate (ADC), trastuzumab deruxtecan (T-DXd), demonstrating robust antitumor activity and the ability to overcome resistance in HER2-low breast cancer models.
CRDF FAQ
6 questionsWhat does Cardiff Oncology Inc. do?
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate...Where does CRDF stock trade?
Cardiff Oncology Inc. (CRDF) is listed on NASDAQ.What sector and industry is CRDF in?
Cardiff Oncology Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about CRDF?
Cardiff Oncology Inc. has had 8 recent analyst actions on file. The most recent action was from Craig Hallum: Hold with a $200.00 price target on 2026-06-03.What companies are similar to CRDF?
Notable peers in the same industry include KURA (Kura Oncology Inc.), IKNA (Ikena Oncology Inc.), SURF (Surface Oncology Inc.), CSBR (Champions Oncology Inc.). Compare CRDF side-by-side with any of them on Quantisnow.How can I track CRDF on Quantisnow?
Quantisnow aggregates Cardiff Oncology Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CRDF to receive live email and push alerts on every new disclosure.